Contents:

Chapter 1: Executive Summary Breast Cancer Therapeutics Breast Cancer Technologies Breast Cancer Markets The Future and Breast Cancer Chapter 2: The Need for Breast Cancer Therapeutics Epidemiology Breast Cancer Types and Stages Causes and Risk Factors Biomarkers and Diagnostics Awareness and Education Treatment Strategies Objectives and Scope Chapter 3: Targets and Therapeutics in Endocrine Therapy Estrogen and the Estrogen Receptor Normal Estrogen Function The Estrogen Receptor Estrogen, The Estrogen Receptor, and Breast Cancer Estrogen and Breast Cancer The Estrogen Receptor and Breast Cancer Categories of Endocrine Therapy Selective Estrogen Receptor Modulators (SERMs) Mode of Action of SERMs Approved SERMs Emerging SERMs Raloxifene Arzoxifene Lasofoxifene Selective Estrogen Receptor Downregulators (SERDs) Mode of Action of SERDs Approved SERDs Aromatase Inhibitors Mode of Action of Aromatase Inhibitors Approved Aromatase Inhibitors Emerging Aromatase Inhibitors LHRH Agonists Mode of Action of LHRH Agonists Approved LHRH Agonists Chapter 4: Innovative Therapy for Breast Cancer Targeting Growth Factors The erbB Receptor Family erbB1/EGFR erbB2/EGFR2/HER2 Targeting Growth Factors (IGF) Targeting Angiogenesis Vascular Endothelial Growth Factor (VEGF) Targeting Farnesylation Targeting the MEK Pathway Targeting the mTOR Pathway Targeting Apoptosis Targeting DNA Synthesis and Repair Targeting the Proteasome Chapter 5: Immunotherapy for Breast Cancer Cancer Vaccines and Breast Cancer Current Approaches in Cancer Vaccine Development Approved and Emerging Cancer Vaccines Approved Cancer Vaccines Emerging Breast Cancer Vaccines Adjuvants Approved and Emerging Monoclonal Antibodies Categories of Monoclonal Antibodies Naked Monoclonal Antibodies Conjugated Monoclonal Antibodies Approved and Emerging Monoclonal Antibodies Approved Monoclonal Antibodies Emerging Monoclonal Antibodies Chapter 6: Chemotherapy for Breast Cancer Historical Timeline Chemotherapy Categorization Antimetabolites Mitotic Inhibitors Alkylating Agents Anthracyclines Topoisomerase II Inhibitors Approved Chemotherapy Drugs for Breast Cancer Emerging Chemotherapy Drugs for Breast Cancer Combination Chemotherapy Chapter 7: Technology and Breast Cancer Gene Cloning and Characterization Gene Expression Profiling Proteomics RNAi Bioinformatics Population Genetics Biomarkers Diagnostics and Prognosis Chapter 8: The Breast Cancer Market Endocrine Therapies Selective Estrogen Receptor Modulators (SERMs) Selective Estrogen Receptor Downregulators (SERDs) Aromatase Inhibitors Arimidex® Femara® Aromasin® Luteinizing Hormone-Releasing Hormone Analogs (LHRH Analogs) Innovative Therapies Immunotherapies The Chemotherapy Market Chapter 9: Future Perspectives Therapeutic Potential Market Potential Breast Cancer Treatment and The Future Breast Cancer and The Patient Summary Chapter 10: Expert Interviews James D. Winkler, Ph.D., Senior Director, Discovery Biology, Array BioPharma Dr. George Blackledge, Senior Oncology Physician, AstraZeneca Dr. Rene Bernards, Chief Scientific Officer, Agendia Dr. Thomas J. Schuetz, Chief Medical Officer and Senior VP of Medical Affairs, Therion Biologics Chapter 11: Company Profiles Aeterna Zentaris Inc Agendia BV American Pharmaceutical Partners, Inc Array BioPharma Inc. AstraZeneca plc Bristol Myers Squibb Dendreon Corporation Eli Lilly and Company Genentech, Inc Genta, Inc. Igeneon Novartis AG Sanofi-aventis Therion Biologics Corporation ViRexx Medical Corp. Chapter 12: References

Summary:

Breast cancer is a complex heterogeneous disease characterized by uncontrolled growth and spread of abnormal cells. It is also very prevalent, with reports from the World Health Organization estimating that more than 1.2 million people will be diagnosed with breast cancer in 2005, worldwide. In the United States, breast cancer is the second most common cancer in women (following skin cancer) with 212,930 new cases estimated for 2004 and an associated 40,840 deaths. In Europe, approximately 200,000 women are diagnosed with breast cancer each year (41,000 in the UK). Consequently, breast cancer is a high-priority research area and is recognized as one of the most aggressively pursued diseases in the history of medicine.

Companies Mentioned

- Aeterna Zentaris Inc - Agendia BV - American Pharmaceutical Partners, Inc - Array BioPharma Inc. - AstraZeneca plc - Bristol Myers Squibb - Dendreon Corporation - Eli Lilly and Company - Genentech, Inc - Genta, Inc. - Igeneon - Novartis AG - Sanofi-aventis - Therion Biologics Corporation - ViRexx Medical Corp.